Clinical trials: Overweight or Obesity; Type 2 Diabetes
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes Mellitus, Obesity
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance
Agonistic activation of fat metabolite responsive G-protein-coupled receptors (GPCR) has been linked to improved glucose metabolism through increased glucose-stimulated-insulin-secreting (GSIS) and incretin release, improved…
- Trial name
- NCT03774095
- Testing
- Hydrolyzed pine nut oil, Hydrolyzed pine nut oil and olive oil
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Karina Vejrum Sørensen
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06972472
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Obesity, Type 2 Diabetes
MagDI Canada Study
The objective of the MagDI Canada study is to evaluate the performance and safety of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial…
- Trial name
- NCT06467955
- Testing
- Magnet System, DI Biofragmentable
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- GT Metabolic Solutions, Inc.
Type 2 Diabetes Mellitus
A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes
It is a phase II, randomized, double-blind, placebo-controlled study of P2202 in patients of type 2 diabetes mellitus, inadequately controlled with a stable dose of metformin or sulfonylurea or both.
- Trial name
- NCT01674348
- Testing
- P2202
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Piramal Enterprises Limited
Obesity, Overweight
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06993792
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a…
- Trial name
- NCT06603571
- Testing
- LY3841136, Tirzepatide
- Where
- 52 sites in United States, Argentina
- Volunteers
- 367 people
- Sponsor
- Eli Lilly and Company
Prediabetes, Type 2 Diabetes
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Given the data on the active ingredients of Totum-63, this research aims to evaluate the effect of its chronic consumption (24 weeks) on glucose and lipid homeostasis and especially on fasting plasma glucose in volunteers with…
- Conditions
- Prediabetes, Type 2 Diabetes, Hypertriglyceridemia, Obesity
- Trial name
- TOTUM-63 TWO (NCT02868177)
- Testing
- Totum-63
- Where
- 6 sites in France, Ireland and 2 more
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Diabetes Mellitus, Type 2, Overweight or Obesity
Effects of Different ''Exercise Snacking'' Modalities on Glycemic Control in Patients With Type 2 Diabetes
Patients with type 2 diabetes (T2DM) face an increased risk of obesity, hypertension, and hyperglycemia, attributed to impaired cardiorespiratory fitness, elevated Hb1AC levels, and impaired lipid status.
- Trial name
- NCT06146036
- Testing
- HIIT snacks, Sprint snacks, Control
- Volunteers
- 20 people
- Sponsor
- University of Nis
Overweight, Diabetes
Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes
- Conditions
- Overweight, Diabetes, PreDiabetes, Obesity
- Trial name
- LIGHT-UP (NCT03058029)
- Testing
- Gelesis200
- Where
- 30 sites in United States, Canada and 6 more
- Volunteers
- 300 people
- Sponsor
- Gelesis, Inc.
Type 2 Diabetes, Overweight or Obesity
Effect of Low-calorie Diets With Different Macronutrient Composition and Macronutrient Distribution in Shift Workers With Prediabetes or Type 2 Diabetes and Overweight or Obesity.
Background and Aims: Shift work, particularly involving night shifts, is associated with increased risk of metabolic disturbances such as type 2 diabetes mellitus (T2DM).
- Conditions
- Type 2 Diabetes, Overweight or Obesity, PreDiabetes
- Trial name
- NCT06912555
- Testing
- Diet
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Universidad de Zaragoza
Type 2 Diabetes Mellitus (T2DM), Overweight or Obese
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT06929156
- Testing
- BGM0504
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity
Effect of a Very Low-Calorie Ketogenic Diet on Gut Microbiota and Fat Distribution
Short-term interventions that use very low-calorie ketogenic diets and meal replacements may be prescribed for selected overweight or obese patients with type 2 diabetes or prediabetes.
- Trial name
- NCT04019431
- Testing
- Whey protein, vegetable protein or animal protein
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Roma La Sapienza
Hypertension, Overweight or Obesity
Education to Decrease in Sodium Intake Evaluated With 24 Hour Urinary Sodium Excretion (RCT)
WHO identifies as an important risk factor and potentially modifiable to high sodium intake (>2g/day 5g salt/day). Also, an insufficient consumption of potassium ( 3.5 g/day).Therefore, the results of this research could be the…
- Conditions
- Hypertension, Overweight or Obesity, Diabetes Mellitus, Type 2
- Trial name
- RCT (NCT04894344)
- Testing
- Education group
- Where
- Mexico
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de Baja California
Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased…
- Trial name
- SURMOUNT-1 (NCT07481747)
- Testing
- Tirzepatide, Reduced-calorie diet
- Where
- China
- Volunteers
- 2,539 people
- Sponsor
- Hudson Biotech
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Atherosclerosis, Cardiovascular Diseases
Semaglutide and Vascular Regeneration
SEMA-VR is a prospective, randomized, 6-month long, open-label study of semaglutide. Approximately 100 participants with type 2 diabetes and/or obesity will be randomized (1:1) to receive semaglutide at escalating doses (up to…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity
- Trial name
- SEMA-VR (NCT05870462)
- Testing
- Semaglutide Pen Injector
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
Obese, Obesity
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index [BMI] ≥ 30 kg/m2) or overweight (BMI…
- Conditions
- Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
- Trial name
- GSBR-1290 (NCT07400588)
- Testing
- Aleniglipron
- Where
- 16 sites in United States
- Volunteers
- 58 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity, Overweight
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07684144
- Testing
- Maridebart Cafraglutide
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 950 people
- Sponsor
- Amgen
Type2 Diabetes, Obesity
mHealth Intervention for Older Adults
This is a pilot study to test the feasibility and acceptability of a self-regulation theory-based mHealth behavior intervention for overweight or obese older adults with T2DM.
- Trial name
- NCT03398590
- Testing
- self-regulation theory-based mHealth behavior intervention
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Boston College